Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Biomaterials

Mouse Gamma Globulin Fraction

Product Sizes
200 mg
£418.00
D609-0200-200MG
About this Product
SKU:
D609-0200
Additional Names:
Mouse -globulin, Plasma Gamma Globulin, Serum Gamma Globulin, Globulin Fractions, Gammaglobulin, mouse gamma fraction
Application:
ELISA, Immunohistochemistry, SDS-PAGE, Western Blot
Buffer:
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride
CE/IVD:
RUO
Concentration:
10 mg/ml
Extra Details:
Mouse Gamma Globulin Fraction consists of the fraction of blood serum which contains whole antibodies as well as other non-albumin plasma proteins. Gamma globulins can be utilized therapeutically to temporarily boost an patient's immunity (such as after an immunosuppressive infection) or to increase the likelihood of kidney transplant acceptance. Gamma Globulin Fraction can be utilized in molecular biology experiments as a control reagent.
Formulation:
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Physical State:
Lyophilized
Shipping Conditions:
Ambient
Specificity:
Mouse Gamma Globulin Fraction was prepared from normal serum by a multi-step process which includes delipidation and salt fractionation followed by extensive dialysis against the buffer stated above. Mouse Gamma Globulin was assayed by immunoelectrophoresis resulted in precipitin arcs against anti-Mouse Serum corresponding to gamma globulins.
Storage Conditions:
Please refer to datasheet
Supplier:
Rockland Inc
Type:
Biomaterials: Blood Products
SMN protein stability in whole blood: short term, long term, and freeze / thaw events. Whole blood of healthy subjects was used in the study. (A) SMN protein was measured in previously frozen, undiluted whole blood samples incubated at 4°C or at room temperature. (B) SMN protein was measured in undiluted whole blood samples of two subjects stored at -80°C or at -20°C. (C) SMN protein levels were measured in samples of two subjects that went through freeze-thaw cycles. *FDA acceptance criteria (below 85%). Primary and secondary detection antibodies were diluted into the following buffer: 50mM Tris, 137.5 mM NaCl, 1% (w/v) BSA, 0.05% (w/v) Tween 20, 0.2% mouse gamma globulin fraction (p/n D609-0100), pH 7.5. Fig 1. PMID: 26953792.
Reproducibility of A Alpha-synuclein standard curves. A. Individual standard curves from 11 independent experiments. B. Mean values of ECL signals standard deviation for defined A Alpha-synuclein concentrations from the 17 experiments. Note that CVs were less than 20% over the entire range. Detection antibody solution: Dilute SULFO-TAG-labeled Syn1 clone 42/A Alpha-synuclein antibody to 1 ug/mL in sample dilution buffer supplemented with 0.1% mouse IgG (p/n D609-0100) and 0.1% goat IgG. Fig. 2. PMID: 30771170.
Development of specific, quantitative and high-throughput assays to measure pS935 LRRK2 and total LRRK2. (A,B) Novel MSD assays to measure pS935 LRRK2 and total LRRK2 levels can detect increasing amounts of recombinant LRRK2 protein; n = 3. (C) Specific detection of pS935 LRRK2 and total LRRK2 was confirmed in WT and LRRK2 KO A549 cells with and without LRRK2 kinase inhibitor treatment (MLi-2, 500 nM, 2 h) measured by western blot analysis. (D,E) Consistent with western blot data, the LRRK2 MSD assays specifically detected pS935 LRRK2 and total LRRK2 in A549 cells; n = 3. MSD signals were normalized for protein concentration, and data are shown as mean +/- SEM with p values: one-way ANOVA with Tukey's multiple comparison test; ***p ≤ 0.001, ****p ≤ 0.0001; AU, arbitrary units. Detection antibodies (15 ul for 384-well) were added to each well diluted in TBST containing 25% MSD blocker A with rabbit (p/n D610-1000) and mouse gamma globin fraction (p/n D609-0100). Fig 1. PMID: 34145320.
IgG infusion in Aid-/- mice ameliorates the exacerbated HFDIO and promotes Treg cells in adipose tissue. Six-week-old male Aid+/+ and Aid-/- mice were fed with HFD for 13 weeks and received purified mouse IgG (p/n D609-0100), IgA (p/n 010-001-341) or PBS by i.v. injection during the first two and last two weeks of the diet. (a) Depiction of the study design. (b) Proportional body weight change post-injection compared with starting body weight. (c-e) Proportion of total body fat assessed by Micro-CT (c) and weight of inguinal adipose tissue (d) and epididymal adipose tissue (e). (f, g) In vivo glucose (f) and insulin (g) tolerance responses from IgG-, IgA- or PBS-infused mice. Proportion of infiltrating Treg cells in the visceral fat, identified by flow cytometry, gated from live, single CD4+ T cells prior to gating on FoxP3+ cells (h). Data shown are pooled from two independent experiments. n = 6-8 per group. Data were assessed for significance using Student's t test (c-e, h) or two-way ANOVA (b, f, g). Data are presented as mean +/- SD. *p<0.05, **p<0.01, ***p<0.001. W, week. Fig. 7. PMID: 35587276.
SDS-Page of MOUSE Gamma Globulin Fraction. Lane 1: Mouse Gamma Globulin Reduced. Lane 2: Molecular Weight Marker. Lane 3: Mouse Gamma Globulin Non-Reduced. Load: 1.0 ug per lane. Predicted/Observed size-Reduced: 55 and 28 kDa. Predicted/Observed size-Non-Reduced: 160 kDa.